nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP2C8—Spironolactone—dilated cardiomyopathy	0.173	0.409	CbGbCtD
Lansoprazole—ABCB1—Lisinopril—dilated cardiomyopathy	0.133	0.314	CbGbCtD
Lansoprazole—ABCB1—Spironolactone—dilated cardiomyopathy	0.117	0.277	CbGbCtD
Lansoprazole—MAPT—LKB1 signaling events—SIK1—dilated cardiomyopathy	0.0125	0.0638	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic cleavage of cellular proteins—DSG2—dilated cardiomyopathy	0.0113	0.0574	CbGpPWpGaD
Lansoprazole—ATP4B—Ion transport by P-type ATPases—PLN—dilated cardiomyopathy	0.0107	0.0547	CbGpPWpGaD
Lansoprazole—ATP4A—Ion transport by P-type ATPases—PLN—dilated cardiomyopathy	0.00957	0.0487	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic execution phase—DSG2—dilated cardiomyopathy	0.00877	0.0447	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic cleavage of cellular proteins—DSP—dilated cardiomyopathy	0.00676	0.0344	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic execution phase—DSP—dilated cardiomyopathy	0.00526	0.0268	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—PSEN2—dilated cardiomyopathy	0.004	0.0204	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—PSEN1—dilated cardiomyopathy	0.00393	0.02	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic cleavage of cellular proteins—LMNA—dilated cardiomyopathy	0.00388	0.0197	CbGpPWpGaD
Lansoprazole—ATP4B—Ion channel transport—RYR2—dilated cardiomyopathy	0.00382	0.0194	CbGpPWpGaD
Lansoprazole—ATP4B—Ion channel transport—PLN—dilated cardiomyopathy	0.00372	0.0189	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—DSG2—dilated cardiomyopathy	0.00366	0.0186	CbGpPWpGaD
Lansoprazole—MAPT—Reelin signaling pathway—ITGB1—dilated cardiomyopathy	0.00353	0.018	CbGpPWpGaD
Lansoprazole—ATP4A—Ion channel transport—RYR2—dilated cardiomyopathy	0.00341	0.0173	CbGpPWpGaD
Lansoprazole—ATP4A—Ion channel transport—PLN—dilated cardiomyopathy	0.00331	0.0169	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—PSEN1—dilated cardiomyopathy	0.0032	0.0163	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—PSEN2—dilated cardiomyopathy	0.00303	0.0154	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic execution phase—LMNA—dilated cardiomyopathy	0.00302	0.0154	CbGpPWpGaD
Lansoprazole—CYP4A11—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00259	0.0132	CbGpPWpGaD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00254	0.0129	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.00246	0.0125	CbGpPWpGaD
Lansoprazole—MAPT—IL-5 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00236	0.012	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00227	0.0116	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—DSP—dilated cardiomyopathy	0.00219	0.0112	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.002	0.0102	CbGpPWpGaD
Lansoprazole—Viral infection—Lisinopril—dilated cardiomyopathy	0.00193	0.00506	CcSEcCtD
Lansoprazole—Polyuria—Furosemide—dilated cardiomyopathy	0.00192	0.00504	CcSEcCtD
Lansoprazole—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00192	0.00504	CcSEcCtD
Lansoprazole—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00192	0.00503	CcSEcCtD
Lansoprazole—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00192	0.00503	CcSEcCtD
Lansoprazole—Cough increased—Lisinopril—dilated cardiomyopathy	0.00191	0.005	CcSEcCtD
Lansoprazole—Alopecia—Spironolactone—dilated cardiomyopathy	0.0019	0.00497	CcSEcCtD
Lansoprazole—Deafness—Furosemide—dilated cardiomyopathy	0.00189	0.00495	CcSEcCtD
Lansoprazole—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00189	0.00495	CcSEcCtD
Lansoprazole—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00187	0.0049	CcSEcCtD
Lansoprazole—Gout—Lisinopril—dilated cardiomyopathy	0.00187	0.0049	CcSEcCtD
Lansoprazole—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00183	0.0048	CcSEcCtD
Lansoprazole—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0018	0.00471	CcSEcCtD
Lansoprazole—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00179	0.00469	CcSEcCtD
Lansoprazole—Thirst—Furosemide—dilated cardiomyopathy	0.00177	0.00465	CcSEcCtD
Lansoprazole—Neck pain—Lisinopril—dilated cardiomyopathy	0.00177	0.00463	CcSEcCtD
Lansoprazole—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00177	0.00463	CcSEcCtD
Lansoprazole—Purpura—Furosemide—dilated cardiomyopathy	0.00175	0.00459	CcSEcCtD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00175	0.0089	CbGpPWpGaD
Lansoprazole—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00174	0.00457	CcSEcCtD
Lansoprazole—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00173	0.00454	CcSEcCtD
Lansoprazole—MAPT—Kit receptor signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00173	0.0088	CbGpPWpGaD
Lansoprazole—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.0017	0.00444	CcSEcCtD
Lansoprazole—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00169	0.00444	CcSEcCtD
Lansoprazole—Wheezing—Lisinopril—dilated cardiomyopathy	0.00169	0.00444	CcSEcCtD
Lansoprazole—Malaise—Spironolactone—dilated cardiomyopathy	0.00169	0.00442	CcSEcCtD
Lansoprazole—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00167	0.00438	CcSEcCtD
Lansoprazole—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00165	0.00432	CcSEcCtD
Lansoprazole—Photophobia—Lisinopril—dilated cardiomyopathy	0.00164	0.00429	CcSEcCtD
Lansoprazole—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00164	0.00429	CcSEcCtD
Lansoprazole—CYP1B1—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00164	0.00833	CbGpPWpGaD
Lansoprazole—Urinary retention—Furosemide—dilated cardiomyopathy	0.00161	0.00421	CcSEcCtD
Lansoprazole—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00158	0.00414	CcSEcCtD
Lansoprazole—Discomfort—Spironolactone—dilated cardiomyopathy	0.00157	0.00412	CcSEcCtD
Lansoprazole—Dehydration—Furosemide—dilated cardiomyopathy	0.00157	0.00411	CcSEcCtD
Lansoprazole—Confusional state—Spironolactone—dilated cardiomyopathy	0.00154	0.00403	CcSEcCtD
Lansoprazole—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00154	0.00403	CcSEcCtD
Lansoprazole—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00153	0.00401	CcSEcCtD
Lansoprazole—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00153	0.004	CcSEcCtD
Lansoprazole—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00152	0.00398	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00152	0.00398	CcSEcCtD
Lansoprazole—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00149	0.00391	CcSEcCtD
Lansoprazole—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00149	0.0039	CcSEcCtD
Lansoprazole—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00147	0.00385	CcSEcCtD
Lansoprazole—MAPT—LPA receptor mediated events—RAC1—dilated cardiomyopathy	0.00146	0.00745	CbGpPWpGaD
Lansoprazole—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00146	0.00383	CcSEcCtD
Lansoprazole—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00146	0.00382	CcSEcCtD
Lansoprazole—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00144	0.00379	CcSEcCtD
Lansoprazole—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00144	0.00378	CcSEcCtD
Lansoprazole—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00143	0.00375	CcSEcCtD
Lansoprazole—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00143	0.00375	CcSEcCtD
Lansoprazole—MAPT—IL-5 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00141	0.0072	CbGpPWpGaD
Lansoprazole—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.0014	0.00368	CcSEcCtD
Lansoprazole—Injury—Lisinopril—dilated cardiomyopathy	0.00138	0.00361	CcSEcCtD
Lansoprazole—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00137	0.0036	CcSEcCtD
Lansoprazole—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00137	0.00358	CcSEcCtD
Lansoprazole—MAPT—IL-2 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00136	0.00692	CbGpPWpGaD
Lansoprazole—Somnolence—Spironolactone—dilated cardiomyopathy	0.00136	0.00355	CcSEcCtD
Lansoprazole—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00135	0.00353	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00133	0.00349	CcSEcCtD
Lansoprazole—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00133	0.00349	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00133	0.00677	CbGpPWpGaD
Lansoprazole—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00132	0.00345	CcSEcCtD
Lansoprazole—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00132	0.00345	CcSEcCtD
Lansoprazole—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00131	0.00343	CcSEcCtD
Lansoprazole—Arthritis—Lisinopril—dilated cardiomyopathy	0.0013	0.00342	CcSEcCtD
Lansoprazole—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.0013	0.0034	CcSEcCtD
Lansoprazole—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00129	0.00659	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00129	0.00658	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00129	0.00658	CbGpPWpGaD
Lansoprazole—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00129	0.00339	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00129	0.00338	CcSEcCtD
Lansoprazole—Renal failure—Furosemide—dilated cardiomyopathy	0.00128	0.00335	CcSEcCtD
Lansoprazole—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00127	0.00333	CcSEcCtD
Lansoprazole—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00127	0.00332	CcSEcCtD
Lansoprazole—Diplopia—Lisinopril—dilated cardiomyopathy	0.00127	0.00332	CcSEcCtD
Lansoprazole—MAPT—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00126	0.00642	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—LMNA—dilated cardiomyopathy	0.00126	0.00641	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00126	0.00329	CcSEcCtD
Lansoprazole—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00126	0.00329	CcSEcCtD
Lansoprazole—Sweating—Furosemide—dilated cardiomyopathy	0.00125	0.00327	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00123	0.00322	CcSEcCtD
Lansoprazole—Face oedema—Lisinopril—dilated cardiomyopathy	0.00122	0.0032	CcSEcCtD
Lansoprazole—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00121	0.00318	CcSEcCtD
Lansoprazole—Urticaria—Spironolactone—dilated cardiomyopathy	0.00121	0.00318	CcSEcCtD
Lansoprazole—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00121	0.00316	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.0012	0.00612	CbGpPWpGaD
Lansoprazole—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00119	0.00311	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00119	0.00603	CbGpPWpGaD
Lansoprazole—Dehydration—Lisinopril—dilated cardiomyopathy	0.00118	0.00309	CcSEcCtD
Lansoprazole—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00115	0.00302	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00115	0.00587	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00115	0.00587	CbGpPWpGaD
Lansoprazole—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00114	0.003	CcSEcCtD
Lansoprazole—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00114	0.003	CcSEcCtD
Lansoprazole—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00114	0.00299	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00114	0.00299	CcSEcCtD
Lansoprazole—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00113	0.00297	CcSEcCtD
Lansoprazole—Visual impairment—Furosemide—dilated cardiomyopathy	0.00113	0.00295	CcSEcCtD
Lansoprazole—CYP4A11—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00113	0.00573	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00112	0.00294	CcSEcCtD
Lansoprazole—Gastritis—Lisinopril—dilated cardiomyopathy	0.00112	0.00294	CcSEcCtD
Lansoprazole—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.0011	0.00289	CcSEcCtD
Lansoprazole—Asthma—Lisinopril—dilated cardiomyopathy	0.00109	0.00287	CcSEcCtD
Lansoprazole—Influenza—Lisinopril—dilated cardiomyopathy	0.00109	0.00287	CcSEcCtD
Lansoprazole—Eye disorder—Furosemide—dilated cardiomyopathy	0.00109	0.00286	CcSEcCtD
Lansoprazole—Tinnitus—Furosemide—dilated cardiomyopathy	0.00109	0.00285	CcSEcCtD
Lansoprazole—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00108	0.00284	CcSEcCtD
Lansoprazole—Pruritus—Spironolactone—dilated cardiomyopathy	0.00108	0.00283	CcSEcCtD
Lansoprazole—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00107	0.00281	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00107	0.00546	CbGpPWpGaD
Lansoprazole—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00107	0.00279	CcSEcCtD
Lansoprazole—Angiopathy—Furosemide—dilated cardiomyopathy	0.00106	0.00278	CcSEcCtD
Lansoprazole—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00105	0.00276	CcSEcCtD
Lansoprazole—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00105	0.00276	CcSEcCtD
Lansoprazole—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00104	0.00273	CcSEcCtD
Lansoprazole—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00104	0.00273	CcSEcCtD
Lansoprazole—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00104	0.00272	CcSEcCtD
Lansoprazole—MAPT—Kit receptor signaling pathway—RAF1—dilated cardiomyopathy	0.00104	0.00527	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00103	0.00524	CbGpPWpGaD
Lansoprazole—Dysuria—Lisinopril—dilated cardiomyopathy	0.00102	0.00268	CcSEcCtD
Lansoprazole—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00102	0.00268	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00102	0.00267	CcSEcCtD
Lansoprazole—Malnutrition—Furosemide—dilated cardiomyopathy	0.00102	0.00266	CcSEcCtD
Lansoprazole—Erythema—Furosemide—dilated cardiomyopathy	0.00102	0.00266	CcSEcCtD
Lansoprazole—Dizziness—Spironolactone—dilated cardiomyopathy	0.00101	0.00264	CcSEcCtD
Lansoprazole—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00101	0.00264	CcSEcCtD
Lansoprazole—CYP1A1—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00101	0.00513	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00101	0.00513	CbGpPWpGaD
Lansoprazole—Flatulence—Furosemide—dilated cardiomyopathy	0.001	0.00263	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000999	0.00262	CcSEcCtD
Lansoprazole—Weight increased—Lisinopril—dilated cardiomyopathy	0.000996	0.00261	CcSEcCtD
Lansoprazole—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000996	0.00261	CcSEcCtD
Lansoprazole—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000988	0.00259	CcSEcCtD
Lansoprazole—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000982	0.00257	CcSEcCtD
Lansoprazole—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000977	0.00256	CcSEcCtD
Lansoprazole—Vomiting—Spironolactone—dilated cardiomyopathy	0.00097	0.00254	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000968	0.00254	CcSEcCtD
Lansoprazole—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000962	0.00252	CcSEcCtD
Lansoprazole—Rash—Spironolactone—dilated cardiomyopathy	0.000962	0.00252	CcSEcCtD
Lansoprazole—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000961	0.00252	CcSEcCtD
Lansoprazole—Renal failure—Lisinopril—dilated cardiomyopathy	0.00096	0.00251	CcSEcCtD
Lansoprazole—Vision blurred—Furosemide—dilated cardiomyopathy	0.000958	0.00251	CcSEcCtD
Lansoprazole—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000957	0.00251	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000957	0.00251	CcSEcCtD
Lansoprazole—Headache—Spironolactone—dilated cardiomyopathy	0.000955	0.0025	CcSEcCtD
Lansoprazole—Jaundice—Lisinopril—dilated cardiomyopathy	0.000952	0.00249	CcSEcCtD
Lansoprazole—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000949	0.00249	CcSEcCtD
Lansoprazole—Anaemia—Furosemide—dilated cardiomyopathy	0.00094	0.00246	CcSEcCtD
Lansoprazole—Sweating—Lisinopril—dilated cardiomyopathy	0.000936	0.00245	CcSEcCtD
Lansoprazole—Agitation—Furosemide—dilated cardiomyopathy	0.000934	0.00245	CcSEcCtD
Lansoprazole—Haematuria—Lisinopril—dilated cardiomyopathy	0.000931	0.00244	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000923	0.00242	CcSEcCtD
Lansoprazole—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000921	0.00241	CcSEcCtD
Lansoprazole—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000916	0.0024	CcSEcCtD
Lansoprazole—Vertigo—Furosemide—dilated cardiomyopathy	0.000913	0.00239	CcSEcCtD
Lansoprazole—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000911	0.00239	CcSEcCtD
Lansoprazole—Leukopenia—Furosemide—dilated cardiomyopathy	0.00091	0.00238	CcSEcCtD
Lansoprazole—Nausea—Spironolactone—dilated cardiomyopathy	0.000906	0.00237	CcSEcCtD
Lansoprazole—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000892	0.00234	CcSEcCtD
Lansoprazole—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000879	0.0023	CcSEcCtD
Lansoprazole—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000876	0.0023	CcSEcCtD
Lansoprazole—Hallucination—Lisinopril—dilated cardiomyopathy	0.000872	0.00228	CcSEcCtD
Lansoprazole—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00087	0.00228	CcSEcCtD
Lansoprazole—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000865	0.00227	CcSEcCtD
Lansoprazole—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000863	0.00226	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00086	0.00225	CcSEcCtD
Lansoprazole—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000859	0.00225	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000847	0.00431	CbGpPWpGaD
Lansoprazole—Dry mouth—Furosemide—dilated cardiomyopathy	0.000847	0.00222	CcSEcCtD
Lansoprazole—Confusional state—Furosemide—dilated cardiomyopathy	0.000837	0.00219	CcSEcCtD
Lansoprazole—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00083	0.00217	CcSEcCtD
Lansoprazole—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000829	0.00217	CcSEcCtD
Lansoprazole—CYP2C19—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000825	0.0042	CbGpPWpGaD
Lansoprazole—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000817	0.00214	CcSEcCtD
Lansoprazole—Shock—Furosemide—dilated cardiomyopathy	0.000816	0.00214	CcSEcCtD
Lansoprazole—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000814	0.00213	CcSEcCtD
Lansoprazole—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000812	0.00213	CcSEcCtD
Lansoprazole—Skin disorder—Furosemide—dilated cardiomyopathy	0.000806	0.00211	CcSEcCtD
Lansoprazole—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000802	0.0021	CcSEcCtD
Lansoprazole—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000795	0.00208	CcSEcCtD
Lansoprazole—Anorexia—Furosemide—dilated cardiomyopathy	0.000791	0.00207	CcSEcCtD
Lansoprazole—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00079	0.00207	CcSEcCtD
Lansoprazole—Chills—Lisinopril—dilated cardiomyopathy	0.000786	0.00206	CcSEcCtD
Lansoprazole—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000783	0.00205	CcSEcCtD
Lansoprazole—Hypotension—Furosemide—dilated cardiomyopathy	0.000775	0.00203	CcSEcCtD
Lansoprazole—Alopecia—Lisinopril—dilated cardiomyopathy	0.000774	0.00203	CcSEcCtD
Lansoprazole—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000768	0.00201	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000765	0.0039	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—FASLG—dilated cardiomyopathy	0.000763	0.00389	CbGpPWpGaD
Lansoprazole—Erythema—Lisinopril—dilated cardiomyopathy	0.000763	0.002	CcSEcCtD
Lansoprazole—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000763	0.002	CcSEcCtD
Lansoprazole—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000758	0.00386	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000755	0.00384	CbGpPWpGaD
Lansoprazole—ATP4B—Ion channel transport—RAF1—dilated cardiomyopathy	0.000754	0.00384	CbGpPWpGaD
Lansoprazole—Flatulence—Lisinopril—dilated cardiomyopathy	0.000752	0.00197	CcSEcCtD
Lansoprazole—Tension—Lisinopril—dilated cardiomyopathy	0.000749	0.00196	CcSEcCtD
Lansoprazole—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000747	0.00196	CcSEcCtD
Lansoprazole—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000745	0.00195	CcSEcCtD
Lansoprazole—Nervousness—Lisinopril—dilated cardiomyopathy	0.000741	0.00194	CcSEcCtD
Lansoprazole—Back pain—Lisinopril—dilated cardiomyopathy	0.000738	0.00193	CcSEcCtD
Lansoprazole—Somnolence—Furosemide—dilated cardiomyopathy	0.000738	0.00193	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—FAS—dilated cardiomyopathy	0.000736	0.00375	CbGpPWpGaD
Lansoprazole—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000733	0.00192	CcSEcCtD
Lansoprazole—CYP1B1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000725	0.00369	CbGpPWpGaD
Lansoprazole—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000721	0.00189	CcSEcCtD
Lansoprazole—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000719	0.00188	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000716	0.00188	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	0.000716	0.00364	CbGpPWpGaD
Lansoprazole—Fatigue—Furosemide—dilated cardiomyopathy	0.000715	0.00187	CcSEcCtD
Lansoprazole—Tremor—Lisinopril—dilated cardiomyopathy	0.000715	0.00187	CcSEcCtD
Lansoprazole—Constipation—Furosemide—dilated cardiomyopathy	0.00071	0.00186	CcSEcCtD
Lansoprazole—Pain—Furosemide—dilated cardiomyopathy	0.00071	0.00186	CcSEcCtD
Lansoprazole—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000708	0.00185	CcSEcCtD
Lansoprazole—Anaemia—Lisinopril—dilated cardiomyopathy	0.000705	0.00185	CcSEcCtD
Lansoprazole—CYP1A1—Oxidative Stress—SOD2—dilated cardiomyopathy	0.000705	0.00359	CbGpPWpGaD
Lansoprazole—Angioedema—Lisinopril—dilated cardiomyopathy	0.000697	0.00183	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000696	0.00354	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.000694	0.00353	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.00069	0.00351	CbGpPWpGaD
Lansoprazole—Malaise—Lisinopril—dilated cardiomyopathy	0.000688	0.0018	CcSEcCtD
Lansoprazole—Vertigo—Lisinopril—dilated cardiomyopathy	0.000685	0.0018	CcSEcCtD
Lansoprazole—Syncope—Lisinopril—dilated cardiomyopathy	0.000684	0.00179	CcSEcCtD
Lansoprazole—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000684	0.00179	CcSEcCtD
Lansoprazole—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000683	0.00179	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000679	0.00178	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000677	0.00344	CbGpPWpGaD
Lansoprazole—Palpitations—Lisinopril—dilated cardiomyopathy	0.000674	0.00177	CcSEcCtD
Lansoprazole—CYP1A1—Oxidative Stress—GPX1—dilated cardiomyopathy	0.000672	0.00342	CbGpPWpGaD
Lansoprazole—ATP4A—Ion channel transport—RAF1—dilated cardiomyopathy	0.000672	0.00342	CbGpPWpGaD
Lansoprazole—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00067	0.00176	CcSEcCtD
Lansoprazole—MAPT—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000666	0.00339	CbGpPWpGaD
Lansoprazole—Cough—Lisinopril—dilated cardiomyopathy	0.000666	0.00174	CcSEcCtD
Lansoprazole—Urticaria—Furosemide—dilated cardiomyopathy	0.000659	0.00173	CcSEcCtD
Lansoprazole—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000656	0.00172	CcSEcCtD
Lansoprazole—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000656	0.00172	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000655	0.00333	CbGpPWpGaD
Lansoprazole—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000649	0.0017	CcSEcCtD
Lansoprazole—Myalgia—Lisinopril—dilated cardiomyopathy	0.000649	0.0017	CcSEcCtD
Lansoprazole—Chest pain—Lisinopril—dilated cardiomyopathy	0.000649	0.0017	CcSEcCtD
Lansoprazole—Anxiety—Lisinopril—dilated cardiomyopathy	0.000647	0.0017	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000646	0.00329	CbGpPWpGaD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000645	0.00169	CcSEcCtD
Lansoprazole—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000642	0.00327	CbGpPWpGaD
Lansoprazole—Discomfort—Lisinopril—dilated cardiomyopathy	0.000642	0.00168	CcSEcCtD
Lansoprazole—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000635	0.00166	CcSEcCtD
Lansoprazole—Confusional state—Lisinopril—dilated cardiomyopathy	0.000628	0.00165	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000623	0.00317	CbGpPWpGaD
Lansoprazole—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000623	0.00163	CcSEcCtD
Lansoprazole—Oedema—Lisinopril—dilated cardiomyopathy	0.000623	0.00163	CcSEcCtD
Lansoprazole—Infection—Lisinopril—dilated cardiomyopathy	0.000619	0.00162	CcSEcCtD
Lansoprazole—Shock—Lisinopril—dilated cardiomyopathy	0.000613	0.00161	CcSEcCtD
Lansoprazole—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000611	0.0016	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000611	0.00311	CbGpPWpGaD
Lansoprazole—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00061	0.0016	CcSEcCtD
Lansoprazole—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000608	0.00159	CcSEcCtD
Lansoprazole—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000605	0.00158	CcSEcCtD
Lansoprazole—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000602	0.00158	CcSEcCtD
Lansoprazole—Asthenia—Furosemide—dilated cardiomyopathy	0.000595	0.00156	CcSEcCtD
Lansoprazole—Anorexia—Lisinopril—dilated cardiomyopathy	0.000593	0.00156	CcSEcCtD
Lansoprazole—Pruritus—Furosemide—dilated cardiomyopathy	0.000587	0.00154	CcSEcCtD
Lansoprazole—CYP4A11—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000583	0.00297	CbGpPWpGaD
Lansoprazole—Hypotension—Lisinopril—dilated cardiomyopathy	0.000582	0.00152	CcSEcCtD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000571	0.00291	CbGpPWpGaD
Lansoprazole—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000568	0.00149	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000567	0.00149	CcSEcCtD
Lansoprazole—Insomnia—Lisinopril—dilated cardiomyopathy	0.000563	0.00148	CcSEcCtD
Lansoprazole—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000559	0.00147	CcSEcCtD
Lansoprazole—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000555	0.00145	CcSEcCtD
Lansoprazole—Somnolence—Lisinopril—dilated cardiomyopathy	0.000553	0.00145	CcSEcCtD
Lansoprazole—Dizziness—Furosemide—dilated cardiomyopathy	0.000549	0.00144	CcSEcCtD
Lansoprazole—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000548	0.00144	CcSEcCtD
Lansoprazole—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000541	0.00142	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000537	0.00141	CcSEcCtD
Lansoprazole—Fatigue—Lisinopril—dilated cardiomyopathy	0.000537	0.00141	CcSEcCtD
Lansoprazole—MAPT—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000536	0.00273	CbGpPWpGaD
Lansoprazole—Pain—Lisinopril—dilated cardiomyopathy	0.000532	0.0014	CcSEcCtD
Lansoprazole—Constipation—Lisinopril—dilated cardiomyopathy	0.000532	0.0014	CcSEcCtD
Lansoprazole—Vomiting—Furosemide—dilated cardiomyopathy	0.000528	0.00138	CcSEcCtD
Lansoprazole—CYP4A11—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000525	0.00267	CbGpPWpGaD
Lansoprazole—Rash—Furosemide—dilated cardiomyopathy	0.000523	0.00137	CcSEcCtD
Lansoprazole—Dermatitis—Furosemide—dilated cardiomyopathy	0.000523	0.00137	CcSEcCtD
Lansoprazole—Headache—Furosemide—dilated cardiomyopathy	0.00052	0.00136	CcSEcCtD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000514	0.00262	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000513	0.00134	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000509	0.00133	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000508	0.00258	CbGpPWpGaD
Lansoprazole—Urticaria—Lisinopril—dilated cardiomyopathy	0.000495	0.0013	CcSEcCtD
Lansoprazole—Nausea—Furosemide—dilated cardiomyopathy	0.000493	0.00129	CcSEcCtD
Lansoprazole—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000492	0.00129	CcSEcCtD
Lansoprazole—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000492	0.00129	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000472	0.0024	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000465	0.00237	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000459	0.0012	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000449	0.00228	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000449	0.00228	CbGpPWpGaD
Lansoprazole—Asthenia—Lisinopril—dilated cardiomyopathy	0.000447	0.00117	CcSEcCtD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000447	0.00227	CbGpPWpGaD
Lansoprazole—Pruritus—Lisinopril—dilated cardiomyopathy	0.00044	0.00115	CcSEcCtD
Lansoprazole—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000426	0.00112	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000422	0.00215	CbGpPWpGaD
Lansoprazole—Dizziness—Lisinopril—dilated cardiomyopathy	0.000412	0.00108	CcSEcCtD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000409	0.00208	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000405	0.00206	CbGpPWpGaD
Lansoprazole—Vomiting—Lisinopril—dilated cardiomyopathy	0.000396	0.00104	CcSEcCtD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000393	0.002	CbGpPWpGaD
Lansoprazole—Rash—Lisinopril—dilated cardiomyopathy	0.000393	0.00103	CcSEcCtD
Lansoprazole—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000392	0.00103	CcSEcCtD
Lansoprazole—Headache—Lisinopril—dilated cardiomyopathy	0.00039	0.00102	CcSEcCtD
Lansoprazole—Nausea—Lisinopril—dilated cardiomyopathy	0.00037	0.000969	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000366	0.00186	CbGpPWpGaD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000365	0.00186	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000354	0.0018	CbGpPWpGaD
Lansoprazole—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000333	0.0017	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000324	0.00165	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000324	0.00165	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TNF—dilated cardiomyopathy	0.000313	0.00159	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ANKRD1—dilated cardiomyopathy	0.00031	0.00158	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000308	0.00157	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000308	0.00157	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000308	0.00157	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	0.000308	0.00157	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000296	0.00151	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	0.000293	0.00149	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—TAZ—dilated cardiomyopathy	0.000292	0.00148	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000291	0.00148	CbGpPWpGaD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000285	0.00145	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000278	0.00141	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000277	0.00141	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000276	0.00141	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ANKRD1—dilated cardiomyopathy	0.000271	0.00138	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000269	0.00137	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000269	0.00137	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000264	0.00135	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—SDHA—dilated cardiomyopathy	0.000264	0.00134	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000262	0.00134	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00026	0.00132	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000258	0.00131	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—TAZ—dilated cardiomyopathy	0.000255	0.0013	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000253	0.00129	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00025	0.00127	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.00024	0.00122	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000238	0.00121	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000234	0.00119	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000232	0.00118	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000231	0.00118	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—SDHA—dilated cardiomyopathy	0.00023	0.00117	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000227	0.00115	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000226	0.00115	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000213	0.00108	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000208	0.00106	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000206	0.00105	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000204	0.00104	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ANKRD1—dilated cardiomyopathy	0.0002	0.00102	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000199	0.00101	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000199	0.00101	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000194	0.000987	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00019	0.000966	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.00019	0.000966	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TAZ—dilated cardiomyopathy	0.000188	0.000956	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000185	0.000943	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000182	0.000925	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000176	0.000897	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	0.000171	0.00087	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SDHA—dilated cardiomyopathy	0.00017	0.000865	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000166	0.000843	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000161	0.000819	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000157	0.000797	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000156	0.000795	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	0.000155	0.000787	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00015	0.000761	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000145	0.00074	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000145	0.00074	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000141	0.000718	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000141	0.000715	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000135	0.000688	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000127	0.000647	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000127	0.000647	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000123	0.000626	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000121	0.000616	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000121	0.000616	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000119	0.000603	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	0.000116	0.000589	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000114	0.000582	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	0.000113	0.000574	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000112	0.00057	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	0.000106	0.00054	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	0.000105	0.000533	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000104	0.000528	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000101	0.000514	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000101	0.000513	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	9.83e-05	0.0005	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	9.83e-05	0.0005	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	9.59e-05	0.000488	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	9.47e-05	0.000482	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	9.26e-05	0.000471	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	9.24e-05	0.00047	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	9.18e-05	0.000467	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.09e-05	0.000463	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	8.71e-05	0.000443	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	8.63e-05	0.000439	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	8.56e-05	0.000436	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	8.36e-05	0.000425	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	7.88e-05	0.000401	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	7.85e-05	0.000399	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	7.81e-05	0.000397	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	7.43e-05	0.000378	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	7.38e-05	0.000376	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GPX1—dilated cardiomyopathy	7.16e-05	0.000365	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CD36—dilated cardiomyopathy	6.98e-05	0.000355	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	6.67e-05	0.00034	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.38e-05	0.000325	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AGT—dilated cardiomyopathy	6.28e-05	0.00032	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GPX1—dilated cardiomyopathy	6.26e-05	0.000319	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.22e-05	0.000316	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CD36—dilated cardiomyopathy	6.1e-05	0.00031	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	6.06e-05	0.000308	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.85e-05	0.000298	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.7e-05	0.00029	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	5.69e-05	0.00029	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.6e-05	0.000285	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AGT—dilated cardiomyopathy	5.49e-05	0.000279	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.46e-05	0.000278	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.22e-05	0.000266	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	5.15e-05	0.000262	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.13e-05	0.000261	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.1e-05	0.000259	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.09e-05	0.000259	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.85e-05	0.000247	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.76e-05	0.000242	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.64e-05	0.000236	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GPX1—dilated cardiomyopathy	4.62e-05	0.000235	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.58e-05	0.000233	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CD36—dilated cardiomyopathy	4.5e-05	0.000229	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	4.2e-05	0.000214	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.18e-05	0.000213	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CD36—dilated cardiomyopathy	4.09e-05	0.000208	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.07e-05	0.000207	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AGT—dilated cardiomyopathy	4.05e-05	0.000206	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.96e-05	0.000202	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AGT—dilated cardiomyopathy	3.68e-05	0.000187	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.57e-05	0.000182	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.95e-05	0.00015	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	2.84e-05	0.000145	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	2.77e-05	0.000141	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	2.61e-05	0.000133	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	2.54e-05	0.000129	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	2.49e-05	0.000127	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	2.33e-05	0.000118	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	2.29e-05	0.000116	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.27e-05	0.000116	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	2.27e-05	0.000115	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.21e-05	0.000113	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	2.14e-05	0.000109	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	2.12e-05	0.000108	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	2.08e-05	0.000106	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	2.07e-05	0.000105	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	2.04e-05	0.000104	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.99e-05	0.000101	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	1.88e-05	9.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	1.86e-05	9.47e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	1.81e-05	9.23e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	1.77e-05	8.98e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	1.59e-05	8.09e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.4e-05	7.12e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.36e-05	6.93e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.23e-05	6.24e-05	CbGpPWpGaD
